长春瑞宾持续静脉输注治疗晚期非小细胞肺癌  

Vinorelbine Continuing Intravenous Infusion to Treat Non-small Cell Lung Cancer of Advanced Stage

作　　者：桑九高 徐小红[2] 

机构地区：[1]江苏省如东县人民医院肿瘤中心,江苏如东226400 [2]江苏省南通市肿瘤医院内科,江苏南通226361

出　　处：《中国临床医学》2008年第5期621-622,共2页Chinese Journal of Clinical Medicine

摘　　要：目的:分析长春瑞宾持续120h静脉输注加顺铂联合治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法:长春瑞宾用量按50mg/m2计算,首剂负荷量10mg加入0.9%氯化钠液40mL中缓慢静脉推注10min以上,然后将余量加入0.9%氯化钠液250mL中持续匀速静脉输注120h;顺铂30mg·m-2,d1-3。治疗NSCLC41例,男性28例,女性13例;肺腺癌31例,鳞癌10例。19例初治,22例复治。结果:CR1例,PR16例,总有效率为41.5%,中位生存期34周,1年生存率为34.1%,中位进展时间21周。剂量限制性毒性为骨髓抑制。101个化疗周期中,白细胞下降为85.1%(86/101),其中Ⅲ-Ⅳ°为21.8%(22/101),血小板和血红蛋白亦有不同程度的下降。结论:长春瑞宾持续120h静脉输注与常规d1,8静注治疗晚期NSCLC的近期有效率较好,不良反应较小,值得临床进一步研究。Objective：To retrospectively analyze the curative effect and side reaction of Vinorelbine （NVB） continuing intravenous infusion （c. i. v） for 120 hours in combination with Cisplatin to treat non-small cell lung cancer （NSCLC） of advanced stage. Methods： NVB, total 50mg/m^2, the first loading dose of 10mg NVB adding 40ml normal sodium （NS）, intravenous in jeering （i. v） slowly for 10 minutes, and the surplus NVB adding 250ml NS c. i. v for 120 hours; Cisplatin, 30mg/m^2·d, d^1-3. To treat NSCLC of 41 examples： 28 males, 13 females; 31 adenocarcinomas, 10 squamous cell carcinomas; 19 initial treatments, 22 retreatments. Results： CR1, PR 16; the total effective rate was 41.5%; the ms survival time was 34 weeks; the survival rate for 1 year was 34.1%; and ms-advanced time was 21 weeks. The dose-restricted-toxicity was myelosuppression. In 101 chemotherapy＇s cicle Hypolekocytosis was 85.1% （86/101）, and Ⅲ-Ⅳ degree of hypolekocytosis was 21.8% （22/101）. Besides that, platelet and hemoglobin decreased in different degree. Conclusion：To compare with NVB i. v d^1-8 , NVB c. i. v for 120 hours has a better effect on treating NSCLC, which has tow side reaction and may be worth further studying.

关 键 词：长春瑞宾 持续静脉输注 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]